Table 5

Topics reported as being "very important" or "quite important" for the National Ethics Committees (NECs).

Topics

Numbers of NECs reporting topic (%)


Monitoring and oversight

87% (13/15)

Assessment of understanding of informed consent

80% (12/15)

Privacy and confidentiality

80% (12/15)

Provision of appropriate risk reduction measures

80% (12/15)

Assessment of cultural sensitivity for informed consent

73% (11/15)

Placebo controlled trials

73% (11/15)

Determination of appropriate subject selection in vulnerable populations

67% (10/15)

Assessment of anticipated benefits

67% (10/15)

Community participation

67% (10/15)

Determinations to conduct Phase I, II, and III clinical trials in a country or community

60% (9/15)

Incentives for participation

60% (9/15)


Abou-Zeid et al. BMC Medical Ethics 2009 10:8   doi:10.1186/1472-6939-10-8

Open Data